Exelixis price to free cash flow EXEL

Market value divided by free cash flow over the last twelve months, since 2016.

Today, Oct 23, 2026: 13.6×
10-year median: 18.6×
Against its 10-year history: 19th; percentile: 0 is its lowest day, 100 its highest
10-year range: 9.0× to 78.3×
Peer median: 27.7×

Exelixis' price to free cash flow is 13.6× as of Oct 23, 2026.

That is below its ten-year median of 18.6×, lower than on 81% of days in the last ten years.

Over that time it ranged from 9.0× in Mar 2020 to 78.3× in Mar 2017.

The median for 10 biotech stocks of a similar size is 27.7×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	13.6×	10.8×	15.5×
2025	15.9×	13.3×	23.9×
2024	22.3×	18.2×	29.7×
2023	20.3×	15.4×	24.4×
2022	15.1×	12.6×	22.5×
2021	21.0×	18.2×	52.9×
2020	20.1×	9.0×	22.3×
2019	11.8×	9.2×	22.5×
2018	18.4×	15.8×	19.9×
2017	76.0×	51.2×	78.3×
2016	49.8×	19.1×	59.2×

Against its peers

Companies in Biotechnology nearest Exelixis' size, closest first, today.

Company	Price to free cash flow
EXELExelixis	13.6×
NBIXNeurocrine Biosciences	16.7×
HALOHalozyme Therapeutics	17.7×
TECHBIO-TECHNE	43.2×
INCYIncyte	12.2×
UTHRUnited Therapeutics	23.1×
RGENRepligen	89.2×
KRYSKrystal Biotech	35.8×
ALNYAlnylam Pharmaceuticals	37.8×
ONCBeOne Medicines	32.3×
REGNRegeneron Pharmaceuticals	22.0×
Peer median	27.7×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Exelixis

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.